Patent · US Active

Highly efficient influenza matrix (M1) proteins

US9951317B2 · kind B2 · utility

0Cited by

16References

20Claims

0Family size

Assignee

Novavax, Inc. · US

Inventors

Gale Smith · Germantown, US
Yingyun Wu · Clarksburg, US
Michael J. MASSARE · Mount Airy, US
Peter Pushko · Frederick, US
Margaret Nathan · Montgomery Village, US
Thomas Kort · Rockville, US
Robin Robinson · Dickerson, US

Key dates

Filing date	Oct 6, 2016
Grant date	Apr 24, 2018
Priority date	—
Expiry date	Oct 6, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2800/22
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.